Artelo Biosciences

Q2 FY2026 EarningsQ2 FY26 missed consensus on the bottom line, with a GAAP net loss of $2.43M compared to the expected $4.14M, and a GAAP EPS of -$0.89 vs. the -$0.72 expected. While the company maintained zero revenue in line with expectations for a clinical-stage biotech, total operating expenses of $2.51M were significantly lower than anticipated, primarily driven by a $1.0M YoY reduction in R&D spending. Despite the narrower-than-expected dollar loss, EPS missed due to massive share dilution from warrant exercises and equity offerings, with weighted average shares outstanding surging to 2.71M.